MCID: HYP025
MIFTS: 47

Hyperphosphatemia malady

Categories: Metabolic diseases

Aliases & Classifications for Hyperphosphatemia

Aliases & Descriptions for Hyperphosphatemia:

Name: Hyperphosphatemia 12 29 52 42 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050459
MeSH 42 D054559
NCIt 47 C113750
SNOMED-CT 64 20165001
UMLS 69 C0085681

Summaries for Hyperphosphatemia

MalaCards based summary : Hyperphosphatemia is related to pseudohypoparathyroidism, type ib and pseudohypoparathyroidism ic. An important gene associated with Hyperphosphatemia is FGF23 (Fibroblast Growth Factor 23), and among its related pathways/superpathways are Signaling by FGFR2 and Endochondral Ossification. The drugs Alendronate and Calcium acetate have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and smooth muscle, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 71 Hyperphosphatemia is an electrolyte disturbance in which there is an abnormally elevated level of... more...

Related Diseases for Hyperphosphatemia

Diseases related to Hyperphosphatemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 97)
id Related Disease Score Top Affiliating Genes
1 pseudohypoparathyroidism, type ib 31.4 GNAS PTH STX16
2 pseudohypoparathyroidism ic 31.2 GNAS PTH STX16
3 calcinosis 30.3 FGF23 KL PTH
4 tumoral calcinosis, hyperphosphatemic, familial 11.9
5 hypoparathyroidism, familial isolated 10.9
6 hypoparathyroidism-retardation-dysmorphism syndrome 10.7
7 hypocalcemia, autosomal dominant 10.7
8 pseudohypoparathyroidism ia 10.7
9 kidney disease 10.3
10 lymphangioleiomyomatosis 10.2 FGF23 SLC34A1
11 peroxisome biogenesis disorder 2b 10.2 FGF23 GALNT3
12 oligospermia 10.2 FGF23 KL
13 y chromosome detection 10.2 PTH VDR
14 hyperostosis 10.2
15 opthalmoplegia mental retardation lingua scrotalis 10.2 FGF23 PTH
16 cole disease 10.2 GALNT3 MGP
17 peritonitis 10.1
18 prostate cancer, hereditary, x-linked 2 10.1 FGF23 SLC34A1 VDR
19 maroteaux stanescu cousin syndrome 10.1 FGF23 RUNX2
20 inclusion-cell disease 10.1 GNAS STX16
21 donnai-barrow syndrome 10.1 FGF23 GALNT3 KL
22 joubert syndrome 9 10.1 FGF23 PTH SLC34A1
23 feigenbaum bergeron richardson syndrome 10.1 FGF23 GALNT3 KL
24 hyperparathyroidism 10.1
25 opportunistic bacterial infectious disease 10.1 FGF23 PTH SLC34A1
26 osseous heteroplasia, progressive 10.1 FGF23 GNAS
27 acth-independent macronodular adrenal hyperplasia 10.1 GNAS RUNX2
28 prediabetes syndrome 10.1 FGF23 PTH
29 leukemia 10.1
30 macrocephaly/megalencephaly syndrome, autosomal recessive 10.1 GCM2 PTH
31 chronic myocardial ischemia 10.1 FGF23 PTH VDR
32 acrorenal syndrome 10.1 PTH RUNX2 VDR
33 dysbaric osteonecrosis 10.1 PTH RUNX2 VDR
34 osteochondrodysplasia 10.0 KL PTH VDR
35 obesity, severe bmiq9 10.0 GNAS PTH STX16
36 intracranial thrombosis 10.0 GNAS PTH STX16
37 esophageal leukoplakia 10.0 GNAS PTH STX16
38 prune belly syndome 10.0 GCM2 PTH
39 deafness, nonsyndromic, modifier 1 10.0 CASR VDR
40 striatonigral degeneration 10.0 CASR PTH
41 orbit lymphoma 10.0 FGF23 GALNT3 KL PTH
42 ischemic bone disease 10.0 FGF23 PTH RUNX2 VDR
43 lymphoblastic leukemia 10.0
44 familial tumoral calcinosis 10.0
45 interstitial nephritis 10.0 PTH SLC34A1
46 familial chronic myelocytic leukemia-like syndrome 9.9 CASR PTH
47 childhood absence epilepsy 9.9 FGF23 GALNT3 KL MGP
48 lactic acidosis 9.9
49 uremia 9.9
50 multiple myeloma 9.9

Graphical network of the top 20 diseases related to Hyperphosphatemia:



Diseases related to Hyperphosphatemia

Symptoms & Phenotypes for Hyperphosphatemia

MGI Mouse Phenotypes related to Hyperphosphatemia:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.18 VDR CASR FGF23 GALNT3 GNAS KL
2 homeostasis/metabolism MP:0005376 10.17 VDR CASR FGF23 GALNT3 GCM2 GNAS
3 endocrine/exocrine gland MP:0005379 10.15 CASR FGF23 GALNT3 GCM2 GNAS KL
4 cardiovascular system MP:0005385 10.14 GNAS KL MGP PTH RUNX2 VDR
5 hematopoietic system MP:0005397 10.06 CASR FGF23 GALNT3 GNAS KL PTH
6 immune system MP:0005387 10.01 CASR FGF23 GALNT3 GNAS KL PTH
7 craniofacial MP:0005382 10 GALNT3 GCM2 GNAS PTH RUNX2 VDR
8 digestive/alimentary MP:0005381 9.99 CASR FGF23 GALNT3 KL RUNX2 VDR
9 mortality/aging MP:0010768 9.96 CASR FGF23 GCM2 GNAS KL MGP
10 integument MP:0010771 9.91 CASR FGF23 GALNT3 GNAS KL RUNX2
11 limbs/digits/tail MP:0005371 9.87 FGF23 GALNT3 GNAS KL PTH RUNX2
12 muscle MP:0005369 9.7 CASR GNAS KL MGP RUNX2 SLC34A1
13 renal/urinary system MP:0005367 9.61 CASR FGF23 GALNT3 GCM2 GNAS KL
14 skeleton MP:0005390 9.36 VDR CASR FGF23 GALNT3 GCM2 GNAS

Drugs & Therapeutics for Hyperphosphatemia

Drugs for Hyperphosphatemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
2
Calcium acetate Approved Phase 4,Phase 3,Phase 1 62-54-4
3
Sevelamer Approved Phase 4,Phase 3,Phase 2,Phase 1 52757-95-6, 152751-57-0 3085017
4
Calcium carbonate Approved Phase 4,Phase 3,Phase 2 471-34-1
5
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
6
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
7
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
8
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
9
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 134070 5280453
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 59-30-3 6037
11
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 1 59-67-6 938
12
Nicotinamide Approved, Nutraceutical Phase 4,Phase 2,Phase 1 98-92-0 936
13
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
14 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
16 Chelating Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Ergocalciferols Phase 4,Phase 2
18 Hormones Phase 4,Phase 3
19 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
20 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
21 vitamin d Phase 4,Phase 3,Phase 2
22 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
23 Antacids Phase 4,Phase 3,Phase 2
24 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2
25 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Hydroxycholecalciferols Phase 4
27 Vasoconstrictor Agents Phase 4,Phase 2
28 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
29 Anticholesteremic Agents Phase 4
30 Antimetabolites Phase 4,Phase 2,Phase 1
31 Atorvastatin Calcium Phase 4 134523-03-8
32 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
33 Hypolipidemic Agents Phase 4,Phase 2,Phase 1
34 Lipid Regulating Agents Phase 4,Phase 2,Phase 1
35 Liver Extracts Phase 4
36 Calcimimetic Agents Phase 4
37 Cinacalcet Hydrochloride Phase 4
38 Hormone Antagonists Phase 4
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
40 Nicotinic Acids Phase 4,Phase 2,Phase 1
41 Vasodilator Agents Phase 4,Phase 2,Phase 1
42 Vitamin B Complex Phase 4,Phase 2,Phase 1
43 Anticoagulants Phase 4,Phase 3,Phase 2,Phase 1
44 Ferric Compounds Phase 4,Phase 3,Phase 2
45 Hematinics Phase 4,Phase 3,Phase 2
46 Protective Agents Phase 4,Phase 2
47 Antioxidants Phase 4
48 Calciferol Nutraceutical Phase 4,Phase 2
49 Vitamin D2 Nutraceutical Phase 4,Phase 2
50 Folate Nutraceutical Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 159)
id Name Status NCT ID Phase
1 Alendronate for Vascular Calcification in Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4
2 More Frequent Dialysis (>3 Treatments Per Week) Unknown status NCT00575497 Phase 4
3 Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan Completed NCT01412398 Phase 4
4 Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Completed NCT01755078 Phase 4
5 Phosphate Kinetic Modeling 2 Completed NCT01252771 Phase 4
6 Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease Completed NCT00160121 Phase 4
7 Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism Completed NCT00307840 Phase 4
8 Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism Completed NCT01115543 Phase 4
9 Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4
10 Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis Completed NCT00091481 Phase 4
11 Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients Completed NCT01427907 Phase 4
12 CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients Completed NCT00211939 Phase 4
13 Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4
14 20070360 Incident Dialysis Completed NCT00803712 Phase 4
15 Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia Recruiting NCT02836184 Phase 4
16 A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Recruiting NCT02661295 Phase 4
17 Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease Recruiting NCT02209636 Phase 4
18 Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia Enrolling by invitation NCT02237534 Phase 4
19 The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis Not yet recruiting NCT03163576 Phase 4
20 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients Not yet recruiting NCT03079869 Phase 4
21 Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5 Terminated NCT00452478 Phase 4
22 Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol Terminated NCT01725113 Phase 4
23 Vitamin D and Carboxy PTH Fragments in Coronary Calcification Withdrawn NCT00502268 Phase 4
24 Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction Unknown status NCT01357317 Phase 3
25 A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01833494 Phase 3
26 An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD) Completed NCT02675998 Phase 3
27 Open Study of BAY77-1931 (Lanthanum Carbonate) in Continuous Ambulatory Peritoneal Dialysis Patients Completed NCT01518387 Phase 3
28 Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate Completed NCT01514851 Phase 3
29 Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00772382 Phase 3
30 A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850602 Phase 3
31 Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis Completed NCT00892749 Phase 3
32 A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia Completed NCT01852682 Phase 3
33 A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia Completed NCT01850641 Phase 3
34 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742611 Phase 3
35 A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis Completed NCT01742585 Phase 3
36 A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia Completed NCT00416520 Phase 3
37 A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia Completed NCT00542815 Phase 3
38 A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis Completed NCT01017276 Phase 3
39 A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis Completed NCT01057407 Phase 3
40 A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia Completed NCT00506441 Phase 3
41 Long-term Study in Chronic Kidney Disease (Extension From Study 14817) Completed NCT01187628 Phase 3
42 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Completed NCT00542386 Phase 3
43 Study in Chronic Kidney Disease (CKD) Not on Dialysis Completed NCT01110629 Phase 3
44 A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients Completed NCT01324128 Phase 3
45 Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients Completed NCT01069692 Phase 3
46 A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients Completed NCT01464190 Phase 3
47 A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Completed NCT01074125 Phase 3
48 Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules Completed NCT02027662 Phase 2, Phase 3
49 A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis Completed NCT01191255 Phase 3
50 An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis Completed NCT00681941 Phase 3

Search NIH Clinical Center for Hyperphosphatemia

Cochrane evidence based reviews: hyperphosphatemia

Genetic Tests for Hyperphosphatemia

Genetic tests related to Hyperphosphatemia:

id Genetic test Affiliating Genes
1 Hyperphosphatemia 29

Anatomical Context for Hyperphosphatemia

MalaCards organs/tissues related to Hyperphosphatemia:

39
Kidney, Bone, Smooth Muscle, Colon, Endothelial, Liver, Retina

Publications for Hyperphosphatemia

Articles related to Hyperphosphatemia:

(show top 50) (show all 436)
id Title Authors Year
1
Transient hyperphosphatemia in a child with nephrolithiasis and severe prematurity. ( 28325562 )
2017
2
Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. ( 28533541 )
2017
3
Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients. ( 28321403 )
2017
4
Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. ( 28078600 )
2017
5
Spurious Hyperphosphatemia: A Diagnostic and Therapeutic Challenge. ( 26706383 )
2016
6
Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China. ( 27751671 )
2016
7
Treating hyperphosphatemia - current and advancing drugs. ( 27643443 )
2016
8
Erratum to: Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. ( 27832343 )
2016
9
Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease. ( 27512294 )
2016
10
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( 27933339 )
2016
11
Ornithine is a key mediator in hyperphosphatemia-mediated human umbilical vein endothelial cell apoptosis: Insights gained from metabolomics. ( 26773858 )
2016
12
Short-Term PTH(1-34) Therapy in Children to Correct Severe Hypocalcemia and Hyperphosphatemia due to Hypoparathyroidism: Two Case Studies. ( 27957353 )
2016
13
Sevelamer is an Effective Drug in Treating Hyperphosphatemia Due to Tumor Lysis Syndrome in Children: A Developing World Experience. ( 26855510 )
2016
14
Phenotypic and Genotypic Characterization and Treatment of a Cohort with Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome. ( 27164190 )
2016
15
Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients. ( 27121505 )
2016
16
Efficacy and safety of calcium acetate-magnesium carbonate in the treatment of hyperphosphatemia in dialysis patients. ( 27900961 )
2016
17
Severe hyperphosphatemia after oral laxative administration in a 7-year-old patient. ( 27922249 )
2016
18
Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study. ( 27389681 )
2016
19
Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. ( 26668024 )
2016
20
Hyperphosphatemia Management in Patients with Chronic Kidney Disease. ( 27330380 )
2016
21
The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. ( 27651467 )
2016
22
Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho. ( 27837149 )
2016
23
Transient hyperphosphatemia: a benign laboratory disorder in a boy with Gitelman syndrome. ( 27737396 )
2016
24
Hyperphosphatemia. The hidden killer in chronic kidney disease. ( 25629999 )
2015
25
Ferric citrate (auryxia) for the treatment of hyperphosphatemia. ( 25987821 )
2015
26
Human Preosteoblastic Cell Culture from a Patient with Severe Tumoral Calcinosis-Hyperphosphatemia Due to a New GALNT3 Gene Mutation: Study of In Vitro Mineralization. ( 25899975 )
2015
27
Hyperphosphatemia induces cellular senescence in human aorta smooth muscle cells through integrin linked kinase (ILK) up-regulation. ( 26467393 )
2015
28
Additional benefit of dietitian involvement in dialysis staffs-led diet education on uncontrolled hyperphosphatemia in hemodialysis patients. ( 26658792 )
2015
29
Calcium acetate or calcium carbonate for hyperphosphatemia of hemodialysis patients: a meta-analysis. ( 25799184 )
2015
30
Hyperphosphatemia in Dialysis Patients: Beyond Nonadherence to Diet and Binders. ( 26508681 )
2015
31
Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients. ( 26187601 )
2015
32
Novel iron-containing phosphate binders for treatment of hyperphosphatemia. ( 26293683 )
2015
33
Hyperphosphatemia induces protective autophagy in endothelial cells through the inhibition of Akt/mTOR signaling. ( 24797554 )
2015
34
Ferric citrate (Auryxia) for hyperphosphatemia. ( 26633686 )
2015
35
Effect of individual health education on hyperphosphatemia in the Hakkas residential area. ( 26275110 )
2015
36
Iron, Aluminum, and Lanthanum-based Drugs for Treatment of Hyperphosphatemia. ( 25832833 )
2015
37
Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients. ( 26023014 )
2015
38
Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia. ( 26184491 )
2015
39
Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. ( 25422311 )
2015
40
Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. ( 26420678 )
2015
41
Fetuin-A decrease induced by a low-protein diet enhances vascular calcification in uremic rats with hyperphosphatemia. ( 26180236 )
2015
42
Hyperphosphatemia Is an Independent Risk Factor for Mortality in Critically Ill Patients: Results from a Cross-Sectional Study. ( 26252874 )
2015
43
Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia. ( 26244958 )
2015
44
Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat. ( 26452517 )
2015
45
Improving diet recipe and cooking methods attenuates hyperphosphatemia in patients undergoing peritoneal dialysis. ( 26141941 )
2015
46
Advances in pharmacotherapy for hyperphosphatemia in renal disease. ( 26374200 )
2015
47
Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis. ( 26484018 )
2015
48
Wakame (Undaria pinnatifida ) modulates hyperphosphatemia in a rat model of chronic renal failure. ( 25817287 )
2015
49
Hyperphosphatemia, Phosphoprotein Phosphatases, and Microparticle Release in Vascular Endothelial Cells. ( 25745026 )
2015
50
Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness. ( 26336594 )
2015

Variations for Hyperphosphatemia

Expression for Hyperphosphatemia

Search GEO for disease gene expression data for Hyperphosphatemia.

Pathways for Hyperphosphatemia

GO Terms for Hyperphosphatemia

Cellular components related to Hyperphosphatemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 apical plasma membrane GO:0016324 8.92 CASR GNAS KL SLC34A1

Biological processes related to Hyperphosphatemia according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor signaling pathway GO:0008543 9.67 FGF23 GALNT3 KL
2 skeletal system development GO:0001501 9.62 GNAS PTH RUNX2 VDR
3 positive regulation of bone mineralization GO:0030501 9.59 KL PTH
4 embryonic cranial skeleton morphogenesis GO:0048701 9.58 GNAS RUNX2
5 response to cadmium ion GO:0046686 9.58 PTH SLC34A1
6 endochondral ossification GO:0001958 9.57 GNAS RUNX2
7 regulation of bone mineralization GO:0030500 9.56 FGF23 MGP
8 cellular calcium ion homeostasis GO:0006874 9.56 CASR GCM2 PTH VDR
9 response to lead ion GO:0010288 9.55 PTH SLC34A1
10 energy reserve metabolic process GO:0006112 9.54 GNAS KL
11 response to magnesium ion GO:0032026 9.52 FGF23 SLC34A1
12 cellular response to vitamin D GO:0071305 9.51 CASR FGF23
13 cellular response to parathyroid hormone stimulus GO:0071374 9.48 FGF23 SLC34A1
14 response to fibroblast growth factor GO:0071774 9.46 CASR PTH
15 ossification GO:0001503 9.46 CASR MGP RUNX2 SLC34A1
16 positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway GO:0090080 9.43 FGF23 KL
17 phosphate ion homeostasis GO:0055062 9.4 FGF23 SLC34A1
18 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.37 FGF23 VDR
19 cellular phosphate ion homeostasis GO:0030643 9.13 FGF23 GCM2 SLC34A1
20 response to parathyroid hormone GO:0071107 8.8 GNAS PTH SLC34A1

Molecular functions related to Hyperphosphatemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor binding GO:0005104 8.62 FGF23 KL

Sources for Hyperphosphatemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....